NIH NOURISH Autoimmunity Digital Health Challenge 2026–2028: Up to $650,000 in Prizes for Nutrition and Symptom-Tracking Tools

NIH NOURISH Autoimmunity Digital Health Challenge 2026–2028: Up to $650,000 in Prizes for Nutrition and Symptom-Tracking Tools

The National Institutes of Health (NIH) NOURISH Autoimmunity Digital Health Challenge is looking for practical digital tools that help people living with or at risk of autoimmune disease understand the relationship between diet, nutrition, symptoms, and other health information. It is a three-phase prize competition rather than a conventional research grant. The first phase is aimed at prototype development, and later phases will support testing, refinement, and a live demonstration of the strongest tools.

The challenge is relevant to a mixed team: a person with lived experience, a patient advocacy group, a dietitian, a clinician, a scientist, a software developer, or an organization that can bring those perspectives together. NIH is not asking for an abstract nutrition app with a health claim attached. The announcement emphasizes user-centered design, scientific rationale, privacy and security, accessibility, interoperability, and a credible path to use in research or self-monitoring.

Phase 1 opens on October 1, 2026. The detailed submission instructions on the official NIH page state that the completed Phase 1 package must be submitted by December 11, 2026. The same page’s summary timeline displays a Phase 1 submission period ending January 8, 2027, so applicants should check the submission portal and the official announcement immediately before filing. This guide uses December 11 because it is the specific date attached to the upload instructions.

Key details

What the challenge is designed to fund

NOURISH grew out of an earlier NIH ideation challenge. That earlier work identified a need for tools that let people record diet and nutrition while also observing symptoms, flares, medications, sleep, activity, and other health measures. The new challenge moves from collecting ideas toward building and testing usable digital products.

The core use case is integrated monitoring. A submission could help someone record meals and nutritional changes next to disease-specific symptoms, general symptoms, or immune-related outcomes. The official examples include mobile health applications, wearable devices, continuous monitoring tools, remote patient monitoring platforms, digital symptom diaries, electronic patient-reported outcome tools, and AI-enabled decision-support tools. These examples describe the problem space; they do not mean an applicant must include every technology.

The four themes from the earlier ideation work are also useful context. They include the effectiveness of dietary interventions in autoimmune disease; microbiome, immune, and multi-omics mechanisms; personalized and data-driven nutrition; and community voice, landscape assessment, and patient-centered frameworks. A strong Phase 1 prototype can connect to one or more of these areas, but the practical test is whether the proposed tool helps users monitor nutrition and autoimmune health in a way that is scientifically sensible and useful in daily life or research.

The challenge is not an invitation to make treatment recommendations without evidence. A tool that encourages a particular diet should explain what is being measured, distinguish tracking from medical advice, and avoid implying that a correlation proves a treatment effect. The proposal should show how the product supports observation and learning while respecting the limits of the data it collects.

What winners can receive

The prize structure rewards progress rather than only a polished first submission. NIH anticipates awarding up to ten Phase 1 prizes of $20,000 each. Highly meritorious Phase 1 submissions may be invited into Phase 2, where up to five prizes of $30,000 are available. Strong Phase 2 submissions may then proceed to Phase 3, where up to three awards of $100,000 are available.

The maximum amounts add up to the published total purse of $650,000. They are not a guaranteed award for every eligible submission, and the announcement says prizes are awarded at the discretion of the judging panel. NIH also reserves the right not to award prizes if no submissions are considered worthy.

The later stages have a different emphasis. Phase 2 is expected to involve further development, beta testing, and iterative improvements based on user feedback. The exact Phase 2 timing, requirements, and evaluation criteria will be announced when that phase begins, guided by the tools that receive Phase 1 awards. Phase 3 is intended for tools ready for a detailed demonstration and includes a live presentation and demonstration in August–September 2028, in person or virtually as the arrangements allow.

Prize money will be paid by electronic funds transfer and may be subject to federal tax withholding and reporting. NIH encourages, but does not require, participating entities to obtain a free Unique Entity ID through SAM.gov because it can expedite payment. That suggestion is about payment administration, not a stated Phase 1 eligibility requirement.

Who should consider applying

The announcement makes the challenge open to eligible individuals, teams, and entities. That is broad, but broad eligibility does not mean every idea will be competitive. The intended solver community includes people living with autoimmune disease, caregivers, advocacy organizations, dietitians, nutritionists, lifestyle medicine experts, physicians, scientists, software developers, and engineers.

The best fit is likely a team that can demonstrate both technical ownership and meaningful access to end users. A developer with a working prototype may need a patient partner and a scientific advisor. A research group may need someone who understands product usability and accessibility. An advocacy organization may have strong community trust but need a technical partner to turn the concept into a demonstrable tool.

The source does not state a general citizenship restriction for participants. It does state that registration and compliance with the announcement are required, and it imposes special consent rules for participants under 18. A participant under 18 who is not an emancipated youth must include a signed parent or legal guardian consent form. Emancipated youth must self-certify that status and may later need to provide documentation if selected for an award.

Applicants should also be realistic about the product stage. Phase 1 is called Prototype Development, and the materials include a video demonstration of the Phase 1 prototype. A slide deck describing a future app is not the same thing as a working prototype. The official requirements do not prescribe one technology stack or require both mobile platforms in Phase 1, but NIH says a tool operating on only iOS or Android can be eligible for Phase 1 and expects tools advancing to Phase 2 to be capable of operating on both.

Phase 1 timeline and deadline check

The challenge launch date is September 1, 2026, and the Phase 1 submission period is scheduled to open October 1. The judging period is listed as January 14 through February 12, 2027, with winners announced in March 2027. The outline for Phase 2 places submissions in July–December 2027, judging in January–February 2028, and winners in March 2028. Phase 3 is scheduled for April–August 2028 submissions or development work, a live demonstration in September, and final winners in September 2028.

There is one important date issue in the official announcement. Its high-level challenge summary says Phase 1 runs from October 1, 2026 to January 8, 2027. Later, under “Submission Requirements Phase 1,” it says the completed submission package must be submitted through nourishchallenge.org by December 11, 2026. These dates are not interchangeable. The earlier date is safer for planning, but applicants should confirm which date the live portal enforces and whether NIH issues an update.

Do not wait for the submission window to begin before building the team. The registration form, proposal narrative, video, and prototype need to describe the same product and the same intended users. If an advocacy partner or scientific collaborator must review the prototype, schedule that work before October rather than trying to obtain meaningful feedback during the final week.

Required Phase 1 materials

The Phase 1 package has three required parts: the registration form, a written narrative proposal, and a video demonstration. All three are required for a complete submission.

The narrative may be no longer than six pages. It must use one-inch margins, at least 11-point Calibri, and English. NIH advises applicants to address the problem, scientific rationale, intended users, potential impact, feasibility, scalability, user-centered design, privacy, security, accessibility, interoperability, and sustainability. Treat the page limit as a design constraint. A document that spends five pages on background and one page on the actual prototype will not give reviewers enough evidence.

The video should run for three to five minutes. It should name the participant and application, introduce the problem, show the key features and user workflow, identify intended users, and explain why the tool is impactful, feasible, and innovative. The demonstration should show how a user would track diet or nutrition and disease-specific or general symptoms. If the tool handles autoimmune outcomes or immune-related measures, show those as well. NIH says the video does not need to be highly produced, but it must be clear, legible, and easy to follow.

Submission takes place through the Submission tab of nourishchallenge.org. Applicants create an account, enter a title and brief description, acknowledge the rules, and upload the completed registration form, narrative proposal, and video according to the portal prompts. The page specifies PDF copies of the registration form and narrative as part of the package. Review every file after conversion; a broken PDF, inaccessible video, or missing registration attachment can turn a strong idea into an incomplete submission.

How reviewers are likely to read the proposal

The judging criteria give applicants a clear framework. The criteria are weighted equally, so a clever prototype cannot compensate entirely for weak scientific reasoning or poor user engagement.

First, reviewers will ask whether the team understands the problem and has a sound scientific rationale. Explain whose problem is being solved, what the user needs to record, and why those data belong together. A generic food diary does not automatically address autoimmune disease. The proposal should connect each important feature to a real monitoring or research need.

Second, reviewers will consider engagement and user-centered design. NIH specifically wants participation from people living with autoimmune disease and relevant groups such as caregivers, advocacy organizations, clinicians, and scientists. Name who helped shape the prototype, what they tested, what they said, and what changed as a result. “We consulted users” is weaker than describing a concrete design decision that came from user feedback.

Third, potential impact matters. Explain whether the tool could improve self-monitoring, symptom awareness, quality of life, research participation, data collection, or patient-centered care. Keep the claim proportional to the evidence. A Phase 1 prototype can show a credible route to impact without claiming that it has already improved clinical outcomes.

Fourth, assess feasibility and scalability. Reviewers will want to know whether the product can be implemented in research settings, maintained over time, and adapted to more than one autoimmune condition or population. Address privacy and security directly. Explain what data are collected, who can see them, how consent works, and what happens when a user wants to stop sharing information.

Finally, demonstrate innovation. Innovation can be a new way to combine existing measurements, a better workflow for people with fluctuating symptoms, or a credible approach to personalized nutrition data. Novelty alone is not enough. The tool should be meaningfully useful, understandable to its intended users, and grounded in a problem that NIH considers important.

A practical preparation strategy

Start with a narrow first user journey. For example, show how a person records a dietary change, logs symptoms over time, reviews patterns, and decides what information to share with a clinician or research team. That journey makes the prototype easier to test and the video easier to follow.

Build a small evidence file before writing. Collect user feedback, screenshots of the working workflow, a description of the data model, accessibility checks, and a short explanation of the scientific or clinical rationale. If you have conducted a pilot, report what was actually tested and how many users or sessions were involved. If you have not, say that plainly and describe the next test rather than inventing results.

Make the patient partnership visible. A person with lived experience should not appear only in a quotation at the end of the proposal. Show how their input affected the choice of measures, notification design, language, burden of data entry, privacy controls, or interpretation of results. Autoimmune conditions vary widely, so explain whether the tool is designed for one condition first or can support multiple conditions without pretending they are interchangeable.

Use the video to demonstrate, not repeat. The narrative can explain architecture and evidence. The video should show the product in motion: the initial screen, the recording flow, the symptom view, and the user’s next decision. Keep labels large enough to read and narrate what is happening. A simple recording with a stable screen is more useful than a glossy montage that hides the workflow.

Disclose AI use if applicable. NIH permits AI tools in development, but the rules require full disclosure in the submission materials and ask participants to show their own contribution to development and testing. Keep a brief record of where AI assisted, what the team reviewed, and what was changed or verified by people. That record will also help answer questions about data privacy and authorship.

Common mistakes to avoid

The first mistake is treating the challenge as a generic startup pitch. NIH is evaluating a tool for autoimmune disease, nutrition, and health monitoring. A product description focused only on market size or investor interest will leave the scientific and user-centered criteria unanswered.

The second is promising a clinical outcome that the prototype cannot measure. If the product records symptoms and diet, describe that capability. Do not call it a diagnostic tool or imply that it proves a food caused a flare unless the evidence and intended use support that claim.

The third is ignoring accessibility and burden. People with chronic illness may have fatigue, pain, cognitive load, limited dexterity, or changing capacity to enter data. Explain how the workflow stays usable on a difficult day, what can be entered later, and how users can control reminders.

The fourth is overlooking cross-platform planning. One platform is acceptable for Phase 1, but tools advancing to Phase 2 are expected to operate on both iOS and Android. State what is already working and what will be built next.

The fifth is leaving privacy until the last page. Nutrition, symptoms, medications, and wearable data can be sensitive. Describe collection, storage, sharing, deletion, consent, and security in plain language. If a feature is not built yet, label it as a planned control.

The sixth is missing the deadline ambiguity. Save a copy of the NIH announcement, check the portal’s displayed closing time, and submit early enough to resolve account or upload problems. The page says dates may be subject to change, and the summary and detailed instructions currently show different Phase 1 end dates.

Frequently asked questions

Is this a grant or a prize?

It is a prize challenge. Phase 1 prizes are intended to support prototype development, with additional prize stages for selected teams that continue into optimization and live demonstration.

Does the app have to be available on both iOS and Android?

No. NIH says a Phase 1 tool may operate on either iOS or Android. The announcement expects tools that advance to Phase 2 to be capable of operating on both platforms.

Can a person apply alone?

The announcement says the challenge is open to eligible individuals, teams, and entities. A solo applicant can participate if the submission satisfies the rules, but the problem is interdisciplinary and the target community includes lived-experience, clinical, scientific, and technical perspectives. A solo applicant should explain how those perspectives are represented in the work.

Is a Unique Entity ID required?

NIH encourages participating entities to obtain a free UEI through SAM.gov because it can speed prize payment, but the announcement describes this as encouraged rather than required for participation.

Can applicants use AI tools?

Yes, AI use in development is permitted if it is fully disclosed. Applicants should demonstrate their own contributions to development and testing, and source code may be requested for validation and evaluation.

Will NIH own the submitted application?

Participants retain applicable intellectual-property rights. To participate, they must grant the federal government the nonexclusive licenses described in the challenge rules and consent to specified promotional uses if they win, unless they request an opt-out of promotional activities in writing.

Official links and next steps

Read the full NIH NOURISH Autoimmunity Digital Health Challenge announcement before preparing a submission. Use the NOURISH challenge portal for registration and upload instructions. The NIH page is the authoritative source for the rules, prize amounts, judging criteria, and any deadline correction.

If this challenge fits your work, form the team now, select one concrete user journey, and test the prototype with people who live with autoimmune disease. Prepare the six-page narrative and three-to-five-minute demonstration as one coherent story. Most importantly, verify the deadline shown in the live portal because the NIH announcement currently contains both December 11, 2026 and January 8, 2027 as Phase 1 end dates.